IZI Medical Products LLC, which is backed by Shore Capital, has acquired Benvenue Medical Inc’s vertebral augmentation systems. No financial terms were disclosed.
OWINGS MILLS, Md.–(BUSINESS WIRE)–IZI Medical Products, LLC, a leading interventional medical device company, announced it has completed the acquisition of Benvenue Medical, Inc.’s vertebral augmentation systems. The acquisition includes the Kiva®, Kiva® Pilot, and Blazer® devices in addition to other needles, injectors and cements. This acquisition complements IZI Medical Products’ vertebroplasty and bone biopsy lines including the Duro-Ject®, Osteo-Site®, Osteo-Force®, Vertefix® and Murphy® brands of needles, injectors, and cements.
“Benvenue Medical’s Kiva vertebral body implant technology coupled with our vertebroplasty product line will allow us to offer patients a wide range of treatments for various spinal fractures. We will continue to build on their legacy with our dedicated product development team and growing sales network,” said Greg Groenke, CEO of IZI Medical Products.
IZI Medical is the interventional products platform of Shore Capital Partners.
About IZI Medical Products
As a leading innovator, manufacturer, and distributor of quality medical devices, IZI Medical provides the continuity that our healthcare partners need to succeed. Based in Owings Mills, Maryland, just outside Baltimore, IZI is a leading developer, manufacturer, and provider of high quality medical consumable devices used in radiology, radiation therapy, neuro-spine, and image guided surgery procedures. IZI has built a diverse portfolio of products backed by strong intellectual property and currently sells to more than 1,000 domestic customers as well as internationally across 25 countries.
About Shore Capital
Shore Capital Partners is a Chicago-based private equity firm focused exclusively on microcap healthcare investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has approximately $600 million of equity capital under management through various investment vehicles including the recently formed Shore Capital Partners Fund II, L.P. with $190 million of capital commitments.